The study aims at developping and validating an integrated clinico-molecular model for an accurate identification of FL patients who are progression free and progressed, respectively, at 24 months after treatment.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Diagnosis of FL after January 1st, 2004 (chemoimmunotherapy era)
* Availability of tumor material collected before initiation of medical therapy
* Availability of the baseline and follow-up annotations
Exclusion Criteria:
* None.
Primary outcome measure(s)
Accuracy of multilayer personalized stratification model — 24 months after first line treatment Assessment of multilayer personalized stratification model accuracy in the identification of patients who are progression free at 24 months after first line therapy plus the proportion of patients correctly identified as progressed within 24 months after first line therapy
Trial sites (4)
Facility
City
Region
Status
Arcispedale Santa Maria Nuova, AUSL IRCSS, Hematology Department
Reggio Emilia
RE
Azienda Ospedaliera Universitaria Maggiore della Carità
Novara
Italy
Institute of Oncology Research
Bellinzona
Canton Ticino
Institute of Pathology
Locarno
Canton Ticino
More Oncology Institute of Southern Switzerland trials in Switzerland
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
